In this study, the combination of bortezomib and TRAIL induced a synergistic apoptotic response and suppressed cancer/tumor growth of papillary thyroid cancers in vitro and in animal models, suggesting that SKP2 is a potential therapeutic target in aggressive papillary thyroid cancers. Here, SKP2 is linked to neoplasm.